---
title: 'DLBCL: Who is high risk and how should treatment be optimized?'
date: '2023-11-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37922443/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231104180805&v=2.17.9.post6+86293ac
source: Blood
description: Diffuse large B-cell lymphoma (DLBCL) not otherwise specified is the
  most common subtype of large B-cell lymphoma group, with differences in prognosis,
  reflecting heterogeneity in pathological, molecular, and clinical features. Current
  treatment standard is based on multiagent chemotherapy including anthracycline and
  monoclonal antiCD20 antibody, which leads to cure of 60% patients. Recent years
  have brought new insights to the lymphoma biology and helped to refine risk groups.
  Results of ...
disable_comments: true
---
Diffuse large B-cell lymphoma (DLBCL) not otherwise specified is the most common subtype of large B-cell lymphoma group, with differences in prognosis, reflecting heterogeneity in pathological, molecular, and clinical features. Current treatment standard is based on multiagent chemotherapy including anthracycline and monoclonal antiCD20 antibody, which leads to cure of 60% patients. Recent years have brought new insights to the lymphoma biology and helped to refine risk groups. Results of ...